NVAX

Business Context and Reporting Period

Company: Novavax, Inc. (NVAX)
Filing Type: Form 8-K (Current Report)
Reporting Period: Third Quarter ended September 30, 2005
Date of Report: November 8, 2005
Business Overview: Novavax is transitioning from a specialty pharmaceutical company to a product development firm leveraging proprietary drug delivery and vaccine technologies. Key strategic shifts include eliminating its sales force, discontinuing non-core marketing, and focusing resources on Avian Flu vaccine development.

Key Financial Metrics

Liquidity and Capital:
- Cash and cash equivalents as of September 30, 2005: $6.9 million (down from $17.9 million at year-end 2004).
- Convertible notes outstanding: Reduced to $29.0 million following a $6.0 million conversion to equity.
- Pro forma cash position (including subsequent equity raise and licensing payments): Approximately $34.2 million.

Material Changes vs. Prior Period

• Revenue Variance: Q3 2005 revenue increased significantly compared to Q3 2004, primarily because the prior year included a non-recurring $1.3 million reserve for potential returns of vitamin products. Product sales for Gynodiol, AVC, and ESTRASORB also increased.
• Cost of Sales: Increased due to higher product sales volume and a $400,000 idle capacity charge in 2005 (absent in 2004). Nine-month costs included $2.9 million in idle capacity charges.
• Selling & Marketing: Expenses dropped $8.0 million in Q3 and $10.5 million for the nine-month period. This reduction is attributed to the elimination of the sales force, the cessation of marketing efforts, and the lack of ESTRASORB launch costs incurred in 2004.
• Net Loss Comparison: While Q3 net loss remained flat at $2.7 million, the 2004 period included a one-time $11.2 million gain on the redemption of convertible notes, which distorted the prior year's profitability.

Guidance, Outlook, and Material Events

Recent Significant Events

• Equity Capital Raise: Completed an $18.0 million equity offering at $4.30 per share in November 2005. Total new equity raised in 2005 reached $22.0 million.
• ESTRASORB License: Signed an agreement with Esprit Pharma Inc. for North American distribution. Includes $12.5 million in mandatory payments ($2.0 million received, $8.0 million due by Dec 31, 2005, and $2.5 million in Oct 2006) plus double-digit royalties.
• Debt Conversion: Converted $6.0 million of convertible notes to equity, reducing annual interest expense by $285,000. Remaining notes cannot be "put" by bondholders until July 2007.
• Asset Sale: Sold non-core products/inventory to Pharmelle LLC for $2.5 million in September.

Management Commentary and Outlook

Management is aggressively reducing the monthly burn rate by tightening operations and focusing on core technologies. The company is prioritizing the development of an Avian Flu vaccine using recombinant virus-like particle technology due to global public health risks. Cash requirements for the fourth quarter are anticipated to be significantly lower than the average of the first nine months.

Risks and Contingencies

Forward-looking statements involve risks including the ability to obtain adequate financing, results of clinical studies, regulatory compliance, and competition. The company notes that actual results could differ materially from expectations.

Investor Verification Checklist

• Verify the receipt of the $8.0 million ESTRASORB licensing payment due prior to December 31, 2005.
• Confirm the pro forma cash position of $34.2 million following the November equity raise.
• Monitor the progress of the Avian Flu vaccine development and associated R&D spending increases.
• Review the impact of the $2.9 million idle capacity charge on future cost structures as production scales.
• Assess the sustainability of the reduced burn rate following the elimination of the sales force.